Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 1/2022

08-02-2022 | Immunodeficiency

Spectrum of Genetic T-Cell Disorders from 22q11.2DS to CHARGE

Authors: Daniel Urschel, Vivian P. Hernandez-Trujillo

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2022

Login to get access

Abstract

Improved genetic testing has led to recognition of a diverse group of disorders of inborn errors of immunity that present as primarily T-cell defects. These disorders present with variable degrees of immunodeficiency, autoimmunity, multiple organ system dysfunction, and neurocognitive defects. 22q11.2 deletion syndrome, commonly known as DiGeorge syndrome, represents the most common disorder on this spectrum. In most individuals, a 3 Mb deletion of 22q11 results in haploinsufficiency of 90 known genes and clinical complications of varying severity. These include cardiac, endocrine, gastrointestinal, renal, palatal, genitourinary, and neurocognitive anomalies. Multidisciplinary treatment also includes pediatrics/general practitioners, genetic counseling, surgery, interventional therapy, and psychology/psychiatry. Chromosome 10p deletion, TBX1 mutation, CHD7 mutation, Jacobsen syndrome, and FOXN1 deficiency manifest with similar overlapping clinical presentations and T-cell defects. Recognition of the underlying disorder and pathogenesis is essential for improved outcomes. Diagnosing and treating these heterogenous conditions are a challenge and rapidly improving with new diagnostic tools. Collectively, these disorders are an example of the complex penetrance and severity of genetic disorders, importance of translational diagnostics, and a guide for multidisciplinary treatment.
Literature
1.
go back to reference Greenberg F (1993) DiGeorge syndrome an historical review of clinical and cytogenic features. J Med Genet 30:803–806CrossRef Greenberg F (1993) DiGeorge syndrome an historical review of clinical and cytogenic features. J Med Genet 30:803–806CrossRef
3.
go back to reference Bassett AS et al (2011) Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr 159:332.e331–339.e331 Bassett AS et al (2011) Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr 159:332.e331–339.e331
4.
go back to reference McDonald-McGinn DM, Sullivan K (2011) Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome) Medicine 90:1–18 McDonald-McGinn DM, Sullivan K (2011) Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome) Medicine 90:1–18
5.
go back to reference Sellier C et al (2014) Decreased DGCR8 expression and miRNA dysregulation in individuals with 22q11.2 deletion syndrome. PLoS One 9:e103884 Sellier C et al (2014) Decreased DGCR8 expression and miRNA dysregulation in individuals with 22q11.2 deletion syndrome. PLoS One 9:e103884
7.
go back to reference Guna A, Butcher NJ, Bassett AS (2015) Comparative mapping of the 22q11.2 deletion region and the potential of simple model organisms. J Neurodev Disord 7:18 Guna A, Butcher NJ, Bassett AS (2015) Comparative mapping of the 22q11.2 deletion region and the potential of simple model organisms. J Neurodev Disord 7:18
8.
go back to reference Jerome LA, Papaioannou VE (2001) DiGeorge syndrome phenotype in mice mutant for the T-box gene Tbx1. Nat Genet 27:286–291CrossRef Jerome LA, Papaioannou VE (2001) DiGeorge syndrome phenotype in mice mutant for the T-box gene Tbx1. Nat Genet 27:286–291CrossRef
9.
go back to reference Racedo SE et al (2015) Mouse and human CRKL is dosage sensitive for cardiac outflow tract formation. Am J Hum Genet 96:235–244CrossRef Racedo SE et al (2015) Mouse and human CRKL is dosage sensitive for cardiac outflow tract formation. Am J Hum Genet 96:235–244CrossRef
10.
go back to reference McDonald-McGinn DM et al (2013) Hemizygous mutations in SNAP29 unmask autosomal recessive conditions and contribute to atypical findings in patients with 22q11.2DS. J Med Genet 50:80–90 McDonald-McGinn DM et al (2013) Hemizygous mutations in SNAP29 unmask autosomal recessive conditions and contribute to atypical findings in patients with 22q11.2DS. J Med Genet 50:80–90
12.
go back to reference McDonald-McGinn DM et al (2005) The 22q11.2 deletion in African-American patients: an underdiagnosed population? Am J Med.Genet A 134:242–246 McDonald-McGinn DM et al (2005) The 22q11.2 deletion in African-American patients: an underdiagnosed population? Am J Med.Genet A 134:242–246
13.
go back to reference Liu AP et al (2014) Under-recognition of 22q11.2 deletion in adult Chinese patients with conotruncal anomalies: implications in transitional care. Eur J Med Genet 57:306–311 Liu AP et al (2014) Under-recognition of 22q11.2 deletion in adult Chinese patients with conotruncal anomalies: implications in transitional care. Eur J Med Genet 57:306–311
14.
go back to reference Ale H, Beiro Z, Blouin W, Calderon J, Hernandez-Trujillo VP (2020) Pediatric Hispanic versus non-Hispanic patients with partial DiGeorge syndrome. J Allergy Clin Immunol Pract 8(1):383–384CrossRef Ale H, Beiro Z, Blouin W, Calderon J, Hernandez-Trujillo VP (2020) Pediatric Hispanic versus non-Hispanic patients with partial DiGeorge syndrome. J Allergy Clin Immunol Pract 8(1):383–384CrossRef
15.
go back to reference Bassett AS et al (2009) Premature death in adults with 22q11.2 deletion syndrome. J Med Genet 46:324–330 Bassett AS et al (2009) Premature death in adults with 22q11.2 deletion syndrome. J Med Genet 46:324–330
16.
go back to reference Vorstman JA et al (2006) MLPA: a rapid, reliable, and sensitive method for detection and analysis of abnormalities of 22q. Hum Mut 27:814–821CrossRef Vorstman JA et al (2006) MLPA: a rapid, reliable, and sensitive method for detection and analysis of abnormalities of 22q. Hum Mut 27:814–821CrossRef
17.
go back to reference Markert ML et al (2004) Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases. J Allergy Clin Immunol 113(4):734–741CrossRef Markert ML et al (2004) Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases. J Allergy Clin Immunol 113(4):734–741CrossRef
18.
go back to reference Patel K, Akhter J, Kobrynski L, Benjamin Gathmann MA, Davis O, Sullivan KE (2012) International DiGeorge Syndrome Immunodeficiency Consortium. Immunoglobulin deficiencies: the B-lymphocyte side of DiGeorge syndrome. J Pediatr 161(5):950–3 Patel K, Akhter J, Kobrynski L, Benjamin Gathmann MA, Davis O, Sullivan KE (2012) International DiGeorge Syndrome Immunodeficiency Consortium. Immunoglobulin deficiencies: the B-lymphocyte side of DiGeorge syndrome. J Pediatr 161(5):950–3
19.
go back to reference Repetto GM et al (2014) Case fatality rate and associated factors in patients with 22q11 microdeletion syndrome: a retrospective cohort study. BMJ Open 4:e005041 Repetto GM et al (2014) Case fatality rate and associated factors in patients with 22q11 microdeletion syndrome: a retrospective cohort study. BMJ Open 4:e005041
21.
go back to reference Sullivan KE, Jawad AF et al (1998) Lack of correlation between impaired T cell production, immunodeficiency and other phenotypic features in chromosome 22q11.2 deletions syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Immunol Immunopathol 84: 141–146 Sullivan KE, Jawad AF et al (1998) Lack of correlation between impaired T cell production, immunodeficiency and other phenotypic features in chromosome 22q11.2 deletions syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Immunol Immunopathol 84: 141–146
22.
go back to reference Sullivan KE, Burrows E, McDonald-McGinn DM (2016) Healthcare utilization in chromosome 22q11.2 deletion patients with cardiac disease and low T cell counts. Am J Med Genet A 170: 1630–1634 Sullivan KE, Burrows E, McDonald-McGinn DM (2016) Healthcare utilization in chromosome 22q11.2 deletion patients with cardiac disease and low T cell counts. Am J Med Genet A 170: 1630–1634
23.
go back to reference Dyce O et al (2002) Otolaryngologic manifestations of the 22q11.2 deletion syndrome. Arch Otolaryngol Head Neck Surg 128:1408–1412 Dyce O et al (2002) Otolaryngologic manifestations of the 22q11.2 deletion syndrome. Arch Otolaryngol Head Neck Surg 128:1408–1412
24.
go back to reference Weinzimer SA (2001) Endocrine aspects of the 22q11.2 deletion syndrome. Genet Med 3:19–22 Weinzimer SA (2001) Endocrine aspects of the 22q11.2 deletion syndrome. Genet Med 3:19–22
25.
go back to reference Digilio MC, Marino B, Bagolan P, Giannotti A, Dallapiccola B (1999) Microdeletion 22q11 and oesophageal atresia. J Med Genet 36:137–139 Digilio MC, Marino B, Bagolan P, Giannotti A, Dallapiccola B (1999) Microdeletion 22q11 and oesophageal atresia. J Med Genet 36:137–139
26.
go back to reference Eicher PS et al (2000) Dysphagia in children with a 22q11.2 deletion: unusual pattern found on modified barium swallow. J Pediatr 137:158–164 Eicher PS et al (2000) Dysphagia in children with a 22q11.2 deletion: unusual pattern found on modified barium swallow. J Pediatr 137:158–164
27.
go back to reference Mercer-Rosa L, Pinto N, Yang W, Tanel R, Goldmuntz E (2013) 22q11.2 deletion syndrome is associated with perioperative outcome in tetralogy of Fallot. J Thorac Cardiovasc Surg 146:868–873 Mercer-Rosa L, Pinto N, Yang W, Tanel R, Goldmuntz E (2013) 22q11.2 deletion syndrome is associated with perioperative outcome in tetralogy of Fallot. J Thorac Cardiovasc Surg 146:868–873
28.
go back to reference Carotti A et al (2008) Cardiac defects and results of cardiac surgery in 22q11.2 deletion syndrome. Dev Disabil Res Rev 14:35–42 Carotti A et al (2008) Cardiac defects and results of cardiac surgery in 22q11.2 deletion syndrome. Dev Disabil Res Rev 14:35–42
30.
go back to reference Perez EE, Bokszczanin A, McDonald-McGinn D, Zackai EH, Sullivan KE (2003) Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics 112(4):e325. https://doi.org/10.1542/peds.112.4.e325 (PMID: 14523220) Perez EE, Bokszczanin A, McDonald-McGinn D, Zackai EH, Sullivan KE (2003) Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics 112(4):e325. https://​doi.​org/​10.​1542/​peds.​112.​4.​e325  (PMID: 14523220)
37.
go back to reference Jyonouchi S, McDonald-McGinn D, Bale S, Zachai E, Sullivan KE (2009) CHARGE (coloboma, heart defect, atresia choanae,retarded growth and development, genital hypoplasia, ear anomslies/deafness) syndrome and chromosome 22q11.2 deletion syndrome: a comparison of immunologic and nonimmunologic phenotypic features. Pediatrics 123:e871-e877 Jyonouchi S, McDonald-McGinn D, Bale S, Zachai E, Sullivan KE (2009) CHARGE (coloboma, heart defect, atresia choanae,retarded growth and development, genital hypoplasia, ear anomslies/deafness) syndrome and chromosome 22q11.2 deletion syndrome: a comparison of immunologic and nonimmunologic phenotypic features. Pediatrics 123:e871-e877
Metadata
Title
Spectrum of Genetic T-Cell Disorders from 22q11.2DS to CHARGE
Authors
Daniel Urschel
Vivian P. Hernandez-Trujillo
Publication date
08-02-2022
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 1/2022
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-022-08927-z

Other articles of this Issue 1/2022

Clinical Reviews in Allergy & Immunology 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.